MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
20.36
+0.09 (0.44%)
Dec 20, 2024, 4:00 PM EST - Market closed
MBX Biosciences Employees
MBX Biosciences had 27 employees as of December 31, 2023.
Employees
27
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,043,667
Market Cap
680.38M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 27 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CureVac | 1,172 |
| Bioventus | 970 |
| Axogen | 428 |
| Evolus | 273 |
| IRADIMED CORPORATION | 148 |
| Keros Therapeutics | 136 |
| Immunome | 55 |
| Dianthus Therapeutics | 53 |
MBX News
- 4 weeks ago - MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia - GlobeNewsWire
- 7 weeks ago - MBX Biosciences to Participate in Upcoming November Investor Conferences - GlobeNewsWire
- 2 months ago - MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting - GlobeNewsWire
- 3 months ago - MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 3 months ago - U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market - Seeking Alpha
- 3 months ago - MBX Biosciences shares surge 44% in blockbuster Nasdaq debut - Reuters
- 3 months ago - MBX Biosciences raises $163.2 mln in US IPO - Reuters
- 3 months ago - MBX Biosciences Announces Pricing of Initial Public Offering - GlobeNewsWire